122 related articles for article (PubMed ID: 24911493)
1. Behind closed doors.
DeFrancesco L
Nat Biotechnol; 2014 Jun; 32(6):528-35. PubMed ID: 24911493
[No Abstract] [Full Text] [Related]
2. Expose your clinical thinking.
Nat Biotechnol; 2004 Aug; 22(8):927. PubMed ID: 15286628
[No Abstract] [Full Text] [Related]
3. North American regulatory agencies can and should make clinical trial data publicly available.
Persaud N; Doshi P
CMAJ; 2016 Feb; 188(2):96-97. PubMed ID: 26464136
[No Abstract] [Full Text] [Related]
4. Drugmakers prefer silence on test data; firms violate US law by not registering trials.
Vedantam S
Washington Post; 2004 Jul; ():A1, A4. PubMed ID: 15290815
[No Abstract] [Full Text] [Related]
5. Stronger sanctions needed against companies that suppress data.
Roehr B
BMJ; 2004 Jul; 329(7458):132. PubMed ID: 15258068
[No Abstract] [Full Text] [Related]
6. European drug agency to appeal ruling that it stop releasing trial data.
Hawkes N
BMJ; 2016 Sep; 354():i5331. PubMed ID: 27694255
[No Abstract] [Full Text] [Related]
7. New European clinical trial regulations are "unacceptable" to industry.
Davidson S
Nat Biotechnol; 1998 Feb; 16(2):127. PubMed ID: 9487504
[No Abstract] [Full Text] [Related]
8. Clinical trial data: to disclose or not to disclose?
Bouchie A
Nat Biotechnol; 2006 Sep; 24(9):1058-60. PubMed ID: 16964203
[No Abstract] [Full Text] [Related]
9. Government regulators must steward drug transparency.
Herder M
Nat Med; 2014 Aug; 20(8):806. PubMed ID: 25100518
[TBL] [Abstract][Full Text] [Related]
10. The pioneers of transparency.
Adams B
BMJ; 2015 Jan; 350():g7717. PubMed ID: 25555823
[No Abstract] [Full Text] [Related]
11. Best-kept secrets.
Nat Biotechnol; 2014 Jun; 32(6):499. PubMed ID: 24911473
[No Abstract] [Full Text] [Related]
12. A new prescription for drug industry.
Dean M
Lancet; 1993 Apr; 341(8849):883-4. PubMed ID: 8096577
[No Abstract] [Full Text] [Related]
13. Predictable materiality: a need for common criteria governing the disclosure of clinical trial results by publicly-traded pharmaceutical companies.
Cohen K; Cormier JW; Davar MV
J Contemp Health Law Policy; 2013; 29(2):201-32. PubMed ID: 23837261
[No Abstract] [Full Text] [Related]
14. Clinical trial transparency--antidote to weaker off-label-promotion rules?
Outterson K
N Engl J Med; 2014 Jul; 371(1):1-3. PubMed ID: 24988551
[No Abstract] [Full Text] [Related]
15. Out in the open.
Nat Biotechnol; 2005 Feb; 23(2):153. PubMed ID: 15696130
[No Abstract] [Full Text] [Related]
16. Clinical trial data: share and share alike?
Mitka M
JAMA; 2015 Mar; 313(9):881-2. PubMed ID: 25734721
[No Abstract] [Full Text] [Related]
17. Good pharma? Bad pharma? Better pharma.
Hardman M
J R Coll Physicians Edinb; 2014; 44(4):269-72. PubMed ID: 25516893
[No Abstract] [Full Text] [Related]
18. Glaxo agrees to post results of drug trials on web site.
Harris G
N Y Times Web; 2004 Aug; ():C4. PubMed ID: 15540364
[No Abstract] [Full Text] [Related]
19. Investment managers back greater transparency of clinical trials.
Hawkes N
BMJ; 2015 Jul; 351():h4002. PubMed ID: 26207007
[No Abstract] [Full Text] [Related]
20. European ombudsman questions European Medicines Agency over AbbVie redactions.
Watson R
BMJ; 2014 Nov; 349():g6904. PubMed ID: 25406123
[No Abstract] [Full Text] [Related]
[Next] [New Search]
